An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Public ClinicalTrials.gov record NCT03669588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Study identification
- NCT ID
- NCT03669588
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 167 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2018 (Actual)
- Primary completion
- Apr 6, 2020 (Actual)
- Completion
- Apr 6, 2020 (Actual)
- Last update posted
- Feb 8, 2022
2018 – 2020
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 29 | Phoenix | Arizona | 85018 | — |
| Investigator Site 66 | Carlsbad | California | 92011 | — |
| Investigator Site 5 | Los Angeles | California | 90033 | — |
| Investigator Site 49 | Los Angeles | California | 90095 | — |
| Investigator Site 18 | Orange | California | 92868 | — |
| Investigator Site 40 | Palo Alto | California | 94304 | — |
| Investigator Site 59 | San Francisco | California | 94115 | — |
| Investigator Site 58 | Aurora | Colorado | 80045 | — |
| Investigator Site 34 | Jacksonville | Florida | 32209 | — |
| Investigator Site 4 | Tampa | Florida | 33612 | — |
| Investigator Site 30 | Springfield | Illinois | 62702 | — |
| Investigator Site 25 | Iowa City | Iowa | 52242 | — |
| Investigator Site 21 | Kansas City | Kansas | 66160 | — |
| Investigator Site 27 | Boston | Massachusetts | 02115 | — |
| Investigator Site 48 | Detroit | Michigan | 48201 | — |
| Investigator Site 53 | Buffalo | New York | 14202 | — |
| Investigator Site 3 | Chapel Hill | North Carolina | 27599 | — |
| Investigator Site 20 | Cleveland | Ohio | 44195 | — |
| Investigator Site 9 | Portland | Oregon | 97239 | — |
| Investigator Site 17 | Charleston | South Carolina | 29425 | — |
| Investigator Site | Cordova | Tennessee | 38018 | — |
| Investigator Site 44 | Houston | Texas | 77030 | — |
| Investigator Site 6 | San Antonio | Texas | 78229 | — |
| Investigator Site 2 | Charlottesville | Virginia | 22908 | — |
| Investigator Site 16 | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03669588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03669588 live on ClinicalTrials.gov.